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Background: Endometriosis is a benign disease that has malignant properties such as genetic polymorphism, loss control 
of cell proliferation, infiltration, and local spread or to distant places. Several endometriosis studies linking endometrioma/
ovarian endometriosis with an increased risk of ovarian malignancy give rise to a transformation phenomenon of 
endometriotic cysts into malignancy. Bax is a pro apoptotic protein whose expression decreases in a malignancy. This 
decrease is related to the poor prognosis of endometrioma and ovarian carcinoma. This study was aimed to identify the 
expression and the difference of Bax expression between endometrioma and ovarian carcinoma.
Materials and Methods: Fifty of paraffin blocks of endometrioma tissue and ovarian carcinoma (serous, mucinous, clear cell, 
and endometrioid type) were examined by immunohistochemical using Bondmax Full Automatic with specific monoclonal 
antibody to identify Bax expression. The difference of Bax expression score between endometrioma tissue and ovarian 
carcinoma was tested by Mann-Whitney test with significant value was set at p<0.05.
Results: This study found that mean Bax expression score in endometrioma tissue and ovarian carcinoma was 3.88 and 
3.72. No difference of Bax expression between endometrioma tissue and ovarian carcinoma (p>0.05). No difference of Bax 
expression between the clinical stages and histopathological types of ovarian carcinoma (p>0.05).
Conclusion: There are no statistically significant difference in Bax protein expression in ovarian cancer and endometrioma.
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Introduction
Endometrioma is a benign gynecological disease 
characterized by the presence of endometrial tissue in the 
ovary including the gland and the stromal associated with 
pelvic pain and infertility.1 Endometrioma is a pseudocyst 
that develops from the growth of ectopic endometrial tissue 
and progressively invaginates in the ovarian cortex.1,2 
Endometrioma is commonly known as endometriosis 
in ovaries or chocolate cysts because it contains many 
brownish blood debris.3
 Endometriosis often occurs in women of reproductive 
age (8-10%), but it is possible in premenopausal, 
menopausal, and postmenopausal ages. Endometriosis also 
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found in nullipara and women with infertility. As many 
as 15-25% of infertile women in Indonesia are caused by 
endometriosis. Amount of 30% of women with primary 
infertility have endometriosis and 70-80% of women with 
idiopathic infertility are due to endometriosis. The incidence 
of chocolate cysts is 30-40% of the entire population of 
endometriosis.2,4 
 Several  endometriosis  studies  linking  endometrioma 
or  endometriosis  with  an  increased  risk  of  ovarian 
malignancy give rise to a transformation phenomenon 
of endometriosis cysts into malignancy (malignant 
degeneration)5,6 and result in a poor disease prognosis. 
Recent study also report that 9.3% of ovarian cancer 
patients have a history of endometriosis.7 Endometriosis 
is a benign disease that has malignant properties such as 
genetic polymorphism, loss control of cell proliferation, 
infiltration, and local spread or to distant places.8-10 The 
histogenesis theory of endometriotic cysts, including 
coelomic metaplasia, retrograde menstruation, embryonic 
cell rest, induction, lymphatic and vascular dissemination, 
as well as the pattern of chromosomal aberrations in 
endometriosis.6,11,12  
 One of the molecular characteristics of a malignancy is 
resistance to apoptosis which is characterized by increased 
expression of anti-apoptotic protein (Bcl-2), decreased pro 
apoptosis expression (Bcl-2 associated x protein, Bax), and 
inactivation of p53 due to gene mutation.5 Endometriotic 
pathways have similarities in their development to avoid 
apoptosis with increased expression of Bcl-2, decrease in 
Bax13, and inactivity of the p53 gene due to mutations.14-16 
The purpose of this study was to compare Bax expression 
between ovarian endometrioma and ovarian carcinoma.
Materials and methods
This study was an observational analytic study with cross-
sectional design. The study was conducted in Department 
of Obstetrics and Gynecology, H. Adam Malik Hospital, 
Medan, Indonesia, from October to November 2014. 
The samples used were paraffin blocks of endometrioma 
tissue and serous type of ovarian carcinoma, mucinous, 
endometrioid, and clear cells based on histopathology 
examination of post laparotomy and post laparoscopy 
patients at H. Adam Malik Hospital, Medan. Our inclusion 
criteria were no hormonal therapy for endometriomas was 
given before surgery and no chemotherapy was given before 
surgery for ovarian cancer cases (chemo naive). We exclude 
the sample from damaged paraffin blocks. The sample size 
used was 25 paraffin blocks of endometrioma tissue and 25 
paraffin blocks of ovarian carcinoma which were chosen 
non-randomly convenient sampling of available paraffin 
blocks. Information regarding age, parity status, and the 
disease stages was obtained from patient’s medical record. 
 Expression of Bax was examined by immuno-
histochemical using Bondmax Full Automatic with 
specific Bax monoclonal antibody (Cat. No.#6A7, Thermo 
Fisher Scientific, Rockford, USA). Scoring was based on 
examination of all cells on the slide using the Allred score 
guidelines. The score was the sum of the percentage scores 
of cells that are stained or proportion score (PS) and the 
intensity of staining or intensity score (IS). The proportion 
score was graded into six qualitative score groups: 0 = no 
stained cells; 1 = less than 1% stained cells; 2 = 1-10% 
stained cells; 3 = 11-33% stained cells; 4 = 34-66% stained 
cells; and 5 = 67-100% stained cell. The intensity of staining 
was graded into four qualitative score groups: 0 = no stained 
cells; 1 = weak staining intensity; 2 = moderate staining 
intensity; 3 = strong staining intensity. The immunostaining 
results were quantified as follows: 0-2 = negative expression 
and ≥3 = positive expression.17
 The difference of Bax expression between 
endometrioma and ovarian carcinoma was tested by Mann-
Whitney test with significant value was set at p<0.05. 
The accuracy of reading the Bax expression between two 
observers was analyzed using the kappa value and was 
declared valid if more than 75%.
Results
Most of the endometrioma patients were ≤40-years old 
(68%) and the mean age was 34.12 years, while the ovarian 
carcinoma patients were >40-years old (64%) and the mean 
age was 44.28 years. Generally, endometrioma groups were 
nulliparous (76%), while ovarian carcinoma groups were 
multiparous (44%). Types of ovarian carcinoma based on 
histopathological examination were serous cancer (48%), 
endometrioid (24%), mucinous (16%), and clear cells 
(12%) (Table 1).
 A good agreement was found between two pathologists 
(κ = 0.84), therefore the analysis of Bax expression score 
can be used from one pathologist. This study found that 
mean Bax expression score in endometrioma tissue and 
ovarian carcinoma was 3.88 and 3.72. These showed that 
there was an under expression of Bax protein in both cases 
97
Print ISSN: 2527-4384, Online ISSN: 2527-3442DOI: 10.21705/mcbs.v3i2.50Molecular and Cellular Biomedical Sciences, Vol.3 No.2, September 2019, p.95-9
Types n %
 Serous 12 48
 Mucinous 4 16
 Endometrioid 6 24
 Clear cell 3 12
 Total 25 100
Table 1. Histopathological types of ovarian carcinoma.
based on Allred score. There was no difference between Bax 
expression in endometrioma tissue and ovarian carcinoma 
(p>0.05). The mean Bax expression score in early ovarian 
carcinoma was not significantly different from advanced 
ovarian carcinoma (3.88 vs. 3.65) (p>0.05). Due to the 
Bax expression score of clear cell and mucinous ovarian 
carcinoma was constant, analysis of the two groups was not 
carried out. Median value of Bax expression score in serous 
ovarian carcinoma was 4.00 and in endometrioid was 3.00. 
However, this difference was not statistically significant 
(p>0.05) (Table 2). 
Discussion
The transformation phenomenon of endometrioma towards 
malignancy increases the risk of ovarian carcinoma.18 
Several studies have suggested that ovarian carcinoma 
arising from endometriosis. Endometriosis have similar 
Low Up
Endometrioma 3.88 4 0.44 3.7 4.06 0.224
Ovarian carcinoma 3.72 4 0.45 3.53 3.91
Early ovarian carcinoma (stage I) 3.88 4 0.35 3.58 4.17 0.246
Advanced ovarian carcinoma (stage II-IVA) 3.65 4 0.49 3.39 3.9
Endometrioid 3.33 3 0.51 2.79 3.88 0.097
Serous 3.75 4 0.45 3.46 4.04
Clinical stages
Histopathological type
Carcinoma Category
Expression BAX score
p- value95% CI
Mean Median SD
Groups
Table 2. The difference of BAX expression score in endometrioma and ovarian carcinoma, clinical stages, 
and histopathological type.
characteristics with cancer cells. One of the genetic 
similarities of endometrioma with ovarian carcinoma is 
apoptotic resistance which is characterized by a decrease 
of pro apoptotic protein expression5,6 This current study 
provided a comparison of pro apoptotic protein expression, 
Bax, in endometrioma tissue and ovarian carcinoma.
 Several studies have shown that the transformation of 
endometriosis towards ovarian malignancy often occurs in 
type I ovarian carcinoma (endometrioid, clear cell, serous, 
and well differentiated mucinous). Histopathology of ovarian 
carcinoma derived from endometriosis cysts was clear cell 
type, endometrioid, serous, and mucinous.19-24 Accordingly, 
the samples taken in this study were endometrioid, clear 
cell, serous, mucinous adenocarcinoma. 
 This current study showed that there was no 
statistically significant difference between Bax expression 
score in endometrioma and ovarian carcinoma. Bax protein 
was under expression in both tissues. This result indicated 
that although endometrioma has benign features, the 
expression score of Bax proteins looks like a malignancy. 
This was in line with several recent studies. Fauvet, et 
al., found that Bax expression in endometrioma was 
significantly difference with benign ovarian tumors, 
however there was no difference with ovarian carcinoma.25 
Meresman, et al., and Nezhat, et al., also found that there 
was a decrease in Bax expression in endometrioma tissue 
and endometriotic cysts.13,26 A recent study comparing Bax 
expression in endometrioma with ovarian carcinoma also 
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showed no significant difference27, while another study 
found that Bax expression in endometrioma was higher 
than in well differentiated serous ovarian carcinoma.28 The 
discrepancy of the results may be due to the samples used 
in this study not only serous type ovarian carcinoma tissue, 
but also endometrioid, clear cell, and mucinous types which 
are forms of the endometrioma transformation into ovarian 
carcinoma. Bax expression is associated with stages of 
endometrioma and ovarian carcinoma.18 The higher stage of 
both diseases, the lower expression of Bax. 
 An insignificant difference between Bax expression 
in endometrioma and ovarian carcinoma in this study 
shows that endometrioma has molecular similarities with 
ovarian carcinoma in its resistant properties to apoptotic 
signals. Its clinical meaning is endometrioma has similar 
malignancy characteristics as ovarian carcinoma. Therefore, 
endometriomas  tend  to  be  transformed  to  malignant 
specially to type I ovarian carcinoma. A recent study 
found as much as 0.6-1.7% of endometriomas transform 
into a malignancy and the incidence of endometrioma and 
ovarian carcinoma together was 4-29%.29 Several studies 
showed that women with endometrioma have 1.4-1.9 times 
risk greater to become ovarian carcinoma than healthy 
women.8,20,30
 The current study also showed that there was no 
difference in Bax expression between the clinical stage 
of ovarian carcinoma. The result was only a statistical 
representation, not a relationship between the significance 
level of Bax expression based in clinical stage in ovarian 
carcinoma, therefore, other techniques and research 
methods are needed. The result also was not in line with 
the recent study which found that Bax expression in stage I 
and II of ovarian carcinoma was higher than in stage III and 
IV.31 However, this study results were in line with previous 
studies comparing Bax expression in histopathological types 
of ovarian carcinoma. There was no statistical difference 
between Bax expression score in histopathological types of 
ovarian carcinoma.18,31,32 
Conclusion
There are no statistically significant difference in Bax  protein 
expression between ovarian cancer and endometrioma. 
The results also expected to be the basis for further study 
in finding a shared pathway between endometrioma and 
ovarian cancer especially in ovarian cancer that comes from 
malignant transformation of endometrioma tissue.
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